In addition, T cell cytotoxicity assays using activated Jurkat T cells or activated human PBMCs validated that bladder cancer overexpressing BCCE4[G] responded well to the treatment of PD‐L1 antibody (Figure S30D,E, Supporting Information). This evidence concerns the gene EMSLR and urinary bladder cancer.